[go: up one dir, main page]

AR064899A1 - Uso de derivados de acido de piranona sustituidos para producir medicamentos para tratar el sindrome metabolico - Google Patents

Uso de derivados de acido de piranona sustituidos para producir medicamentos para tratar el sindrome metabolico

Info

Publication number
AR064899A1
AR064899A1 ARP080100165A ARP080100165A AR064899A1 AR 064899 A1 AR064899 A1 AR 064899A1 AR P080100165 A ARP080100165 A AR P080100165A AR P080100165 A ARP080100165 A AR P080100165A AR 064899 A1 AR064899 A1 AR 064899A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heterocyclyl
coo
cycloalkyl
Prior art date
Application number
ARP080100165A
Other languages
English (en)
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39232744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064899(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of AR064899A1 publication Critical patent/AR064899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)

Abstract

Reivindicacion 1: El uso de un compuesto de la formula (1), en la cual R1 es H, F, CI, Br, I, OH, CF3, NO2, CN, OCF3, NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, SF5, SO-CH3, COOH, COO-alquilo (C1-6), CONH2, alquilo (C1-20), cicloalquilo (C3-20), alquenilo (C2-20), alquinilo (C2-20), arilo, heterociclo, donde, en los radicales alquilo (C1-20) y alquenilo (C1-20), uno o más grupos -CH2- o -CH- individuales pueden haber sido reemplazados por -O- y donde los radicales alquilo, cicloalquilo, alquenilo, alquinilo, arilo y heterociclilo pueden estar monosustituidos o polisustituidos con F, CI, Br, I, CF3, NO2, N3, CN, =O, COOH, COO-alquilo (C1-6), CONH2, CONH-alquilo (C1-6), CON[alquilo (C1-6)]2, cicloalquilo, alquilo (C1-10), alquenilo (C2-6), alquinilo (C2-6), O-alquilo (C1-6), O-CO-alquilo (C1-6), O-CO-arilo (C1-6), O-CO-heterociclilo (C1-6); PO3H2, P(O)(O-alquilo)2, alquilen (C1-6)-P(O)(O-alquilo)2, O-P(O)(OH)2, O-P(O)(O-alquilo)2, SO3H, SO2-NH2, SO2NH-alquilo (C1-6), SO2N[alquilo (C1-6)]2, S-alquilo (C1-6), S-(CH2)n-arilo, S-(CH2)n-heterociclilo, SO-alquilo (C1-6), SO-(CH2)n-ariIo, SO-(CH2)n-heterociclilo, SO2-alquilo (C1-6), SO2-(CH2)n-arilo, SO2(CH2)n-heterociclilo, SO2-NH(CH2)n-arilo, SO2NH(CH2)n- heterociclilo, SO2-N(alquil (C1-6))(CH2)n-arilo, SO2-N(alquil (C1-6))(CH2)n-heterociclilo, SO2N((CH2)n-arilo)2, SO2-N((CH2)n-heterociclilo)2, donde n = 0-6 y el radical arilo o el radical heterocíclico puede estar sustituido hasta dos veces con F, CI, Br, OH, CF3, SF5, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2; C(NH)(NH2), NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, NH-acilo (C1-7), NH-CO-alquilo (C1-6), NH-COO-alquilo (C1-6), NH-CO-arilo, NH-CO-heterociclilo, NH-COO-arilo, NH-COO- heterociclilo, NH-CO-NH-alquilo (C1-6)), NH-CO-NH-arilo, NH-CO-NH-heterociclilo, N[alquil (C1-6)]-CO-alquilo (C1-6), N[alquil (C1-6)]-COO-alquilo (C1-6), N[alquil (C1-6)]-CO-arilo, N[alquil (C1-6)]-CO-heterociclilo, N[alquil (C1-6)]-COO-arilo, N[alquil (C1-6)]-COO-heterociclilo, N[alquil (C1-6)]-CO-NH-alquilo (C1-6)), N[alquil (C1-6)]-CO-NH-arilo, N[alquil (C1-6)]-CO-NH-heterociclilo, N[alquil (C1-6)]-CO-N(alquilo (C1-6))2, N[alquil (C1-6)]-CO-N(alquil (C1-6))-arilo, N[alquil (C1-6)]-CO- N(alquil (C1-6))-heterociclilo, N[alquil (C1-6)]-CO-N(arilo)2, N[alquil (C1-6)]-CO-N(heterociclilo)2, N(aril)-CO-alquilo (C1-6), N(heterociclil)-CO-alquilo (C1-6), N(aril)-COO-alquilo (C1-6), N(heterociclil)-COO-alquilo (C1-6), N(aril)-CO-arilo, N(heterociclil)-CO-arilo, N(aril)-COO-arilo, N(heterociclil)-COO-arilo, N(aril)-CO-NH-alquilo (C1-6), N(heterociclil)-CO-NH-alquil (C1-6), N(aril)-CO-NH-arilo, N(heterociclil)-CO-NH-arilo, N(aril)-CO-N(alquilo (C1-6)), N(heterociclil)-CO-N(alquilo (C1-6))2, N(aril)-CO-N[alquil (C1-6)]-arilo, N(heterociclil)-CO-N[alquil (C1-6)]-arilo, N(aril)-CO-N(arilo)2, N(heterociclil)-CO-N(arilo)2, arilo, O-(CH2)n-arilo, O-(CH2)n-heterociclilo, donde n = 0 - 6 y donde el radical arilo o heterociclilo puede estar desde monosustituido hasta trisustituido con F, CI, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, SF5, SO2-CH3, COOH, COO-alquilo (C1-6), CONH2; R2 es H, E, CI, Br, I, OH, CF3, NO2, CN, OCF3, NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, SF5, SO2-CH3, COOH, COO-alquilo (C1-6), CONH2, alquilo (C1-20), cicloalquilo (C3-20), alquenilo (C2-20), alquinilo (C1-20), arilo, heterociclo, donde, en los radicales alquilo (C1-20) y alquenilo (C2-20), uno o más grupos -CH2- o -CH- individuales pueden haber sido reemplazados por -O- y donde los radicales alquilo cicloalquilo, alquenilo, alquinilo, arilo y heterociclo pueden estar monosustituidos o polisustituidos con F, CI, Br, I, CF3, NO2, N3, CN, =O, COOH, COO-alquilo (C1-6), CONH2, CONH-alquilo (C1-6), CON[alquilo (C1-6)]2 cicloalquilo, alquilo (C1-10), alquenilo (C2-6), alquinilo (C2-6), O-alquilo (C1-6), O-CO-alquilo (C1-6), O-CO-arilo (C1-6), O-CO-heterociclilo (C1- 6); PO3H2, P(O)(O-alquilo)2, alquilen (C1-6)-P(O)(O-alquilo)2, O-P(O)(OH)2, O-P(O)(O-alquilo)2, SO3H, SO2-NH2, SO2NH-alquilo (C1-6), SO2N[alquilo (C1-6)]2, S-alquilo (C1-6), S-(CH2)n-arilo, S-(CH2)n-heterociclilo, SO-alquilo (C1-6), SO-(CH2)n-arilo, SO-(CH2)n-heterociclilo, SO2-alquilo (C1-6), SO2-(CH2)n-arilo, SO2-(CH2)n-heterociclilo, SO2-NH(CH2)n-arilo, SO2-NH(CH2)n-heterociclilo, SO2-N(alquil (C1-6))(CH2)n-arilo, SO2-N(alquil (C1-6))(CH2)n-heterociclilo, SO2-N((CH2)n-arilo)2, SO2-N((CH2)n- heterociclilo)2, donde n = 0 - 6 y el radical arilo o el radical heterocíclico puede estar sustituido hasta dos veces con F, Cl, Br, OH, CF3, SF5, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2; C(NH)(NH2), NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, NH-acilo (C1-7), NH-CO-alquilo (C1-6), NH-COO-alquilo (C1-6), NH-CO-arilo, NH-CO-heterociclilo, NH-COO-arilo, NH-COO-heterociclilo, NH-CO-NH-alquilo (C1-6)), NH-CO-NH-arilo, NH-CO-NH-heterociclilo, N[alquil (C1-6))-CO-alquilo (C1-6), N[alquil (C1-6)]-COO-alquilo (C1-6), N[alquil (C1-6)]-CO-arilo, N[alquil (C1-6)]-CO-heterociclilo, N[alquil (C1-6)]-COO-arilo, N[alquil (C1-6)]-COO-heterociclilo, N[alquil (C1-6)]-CO-NH-alquilo (C1-6)], N[alquil (C1-6)]-CO-NH-arilo, N[alquil (C1-6)]- CO-NH-heterociclilo, N[alquil (C1-6)]-CO-N(alquilo (C1-6))2, N[alquil (C1-6)]-CO-N(alquil (C1-6))-arilo, N[alquil (C1-6)]-CO-N(alquil (C1-6))-heterociclilo, N[alquil (C1-6)]-CO-N(arilo)2, N[alquil (C1-6)]-CO-N(heterociclilo)2, N(aril)-CO-alquilo (C1- 6), N(heterociclil)-CO-alquilo-(C1-6), N(aril)-COO-alquilo (C1-6), N(heterociclil)-COO-alquilo (C1-6), N(aril)-CO-arilo, N(heterociclil)-CO-arilo, N(aril)-COO-arilo, N(heterociclil)-COO-arilo, N(aril)-CO-NH-alquilo (C1-6), N(heterociclil)CO-NH- alquilo (C1-6), N(aril)-CO-NH-arilo, N(heterociclil)-CO-NH-arilo, N(aril)-CO-N(alquilo (C1-6))2, N(heterociclil)-CO-N(alquilo (C1-6))2, N(aril)-CO-N[alquil (C1-6)]-arilo, N(heterociclil)-CO-N[alquil (C1-6)]-arilo, N(aril)-CO-N(arilo)2, N(heterociclil)-CO-N(arilo)2, arilo, O-(CH2)n-arilo, O-(CH2)n-heterociclilo, donde n = 0 - 6 y donde el radical arilo o heterociclilo puede estar desde monosustituido hasta trisustituido con F, CI, Br, I, OH1 CF3, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, SF5, SO2-CH3, COOH, COO-alquilo (C1-6), CONH2; o bien R1 y R2 forman juntos un anillo de arilo, cicloalquilo o heterociclilo con 3 a 8 miembros, donde el anillo de arilo, cicloalquilo o heterociclilo puede estar sustituido con F, CI, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, SF5, SO2-CH3, COOH, COO-alquilo (C1-6), CONH2 y donde el anillo de arilo, cicloalquilo o heterociclilo puede estar condensado con otro anillo de arilo, cicloalquilo o heterociclico; y sus sales fisiologicamente aceptables, para producir un medicamento para el tratamiento del síndrome metabolico.
ARP080100165A 2007-01-16 2008-01-14 Uso de derivados de acido de piranona sustituidos para producir medicamentos para tratar el sindrome metabolico AR064899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007002260A DE102007002260A1 (de) 2007-01-16 2007-01-16 Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms

Publications (1)

Publication Number Publication Date
AR064899A1 true AR064899A1 (es) 2009-05-06

Family

ID=39232744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100165A AR064899A1 (es) 2007-01-16 2008-01-14 Uso de derivados de acido de piranona sustituidos para producir medicamentos para tratar el sindrome metabolico

Country Status (31)

Country Link
US (1) US8748483B2 (es)
EP (1) EP2120923B1 (es)
JP (1) JP2010515765A (es)
KR (1) KR20090110834A (es)
CN (1) CN101600427A (es)
AR (1) AR064899A1 (es)
AU (1) AU2008207170A1 (es)
BR (1) BRPI0806661A2 (es)
CA (1) CA2675442A1 (es)
CL (1) CL2008000110A1 (es)
CR (1) CR10850A (es)
CY (1) CY1113148T1 (es)
DE (1) DE102007002260A1 (es)
DK (1) DK2120923T3 (es)
DO (1) DOP2009000177A (es)
EC (1) ECSP099518A (es)
ES (1) ES2390513T3 (es)
HR (1) HRP20120763T1 (es)
IL (1) IL199829A0 (es)
MA (1) MA31094B1 (es)
MX (1) MX2009006913A (es)
PE (1) PE20081700A1 (es)
PL (1) PL2120923T3 (es)
PT (1) PT2120923E (es)
RS (1) RS52494B (es)
RU (1) RU2009131058A (es)
SI (1) SI2120923T1 (es)
TN (1) TN2009000275A1 (es)
TW (1) TW200836716A (es)
UY (1) UY30871A1 (es)
WO (1) WO2008086949A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104837823A (zh) * 2012-12-13 2015-08-12 默克专利股份有限公司 作为蛋白质-粘附性活性物质的3-羟基-4-氧代-4h-吡喃或3-羟基-4-氧代-1,4-二氢吡啶衍生物
JP6338276B2 (ja) * 2014-07-10 2018-06-06 学校法人神奈川大学 抗癌剤
KR20240023691A (ko) * 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152148A (en) 1963-01-03 1964-10-06 Dow Chemical Co Preparation of comenic and pyromeconic acids
DE2966702D1 (en) 1978-06-26 1984-03-29 Measurex Corp Method and apparatus for measuring gas, including standardisation
JPS59125644A (ja) 1982-12-29 1984-07-20 Fujitsu Ltd 半導体装置
US4603144A (en) 1984-08-16 1986-07-29 G. D. Searle & Co. Kojic acid ether-ester derivatives
GB8615041D0 (en) * 1986-06-20 1986-07-23 Silver J Pharmaceutical compositions
DE3728602A1 (de) 1987-08-27 1989-03-09 Bayer Ag Faserverstaerktes polyphenylensulfid
DE3728924A1 (de) 1987-08-29 1989-03-09 Bayer Ag Flammwidrige, thermoplastische formmassen auf basis von polycarbonat, polyalkylenterephthalat, pfropfcopolymerisat, fluoriertem polyolefin und phosphorverbindung
DE3729586A1 (de) 1987-09-04 1989-03-16 Ant Nachrichtentech Verfahren zum ausgleichen von durch den doppler-effekt hervorgerufenen laufzeit-verschiebungen der bursts in einem tdma-rahmen sowie anordnung
CA2007414C (en) 1989-04-26 1994-10-25 Clayton James Bennett Iii Method for manipulating elements within a structured document using active intent interpretations
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH06271500A (ja) * 1993-03-23 1994-09-27 Noguchi Kenkyusho コマン酸の製造法
DE19530298C2 (de) * 1995-08-17 1999-07-22 Woerwag Pharma Gmbh Verwendung von Orotsäure zur Prävention und Therapie des metabolischen Syndroms
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
DE60027420T2 (de) 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
DK1177187T3 (da) 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
AU773505B2 (en) 1999-06-18 2004-05-27 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
ATE245636T1 (de) 1999-07-29 2003-08-15 Lilly Co Eli Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
KR20020033778A (ko) 1999-09-01 2002-05-07 로버트 흐라이탁, 미쉘 베스트 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
PT1277736E (pt) 2000-04-28 2007-10-12 Asahi Kasei Pharma Corp Novos compostos bicíclicos
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
DE10033353A1 (de) 2000-07-08 2002-01-24 Aventis Pharma Gmbh Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren
FR2814678B1 (fr) 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
PT1425014E (pt) 2001-08-31 2007-03-30 Sanofi Aventis Deutschland Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar
US6552073B1 (en) 2002-03-01 2003-04-22 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10307004B3 (de) 2003-02-19 2004-08-05 Siemens Ag Verfahren zur Steuerung einer Brennkraftmaschine mit einer Lambda-Regelung

Also Published As

Publication number Publication date
TW200836716A (en) 2008-09-16
IL199829A0 (en) 2010-04-15
AU2008207170A1 (en) 2008-07-24
CY1113148T1 (el) 2016-04-13
PT2120923E (pt) 2012-08-31
US20100144862A1 (en) 2010-06-10
DE102007002260A1 (de) 2008-07-31
ECSP099518A (es) 2009-08-28
PE20081700A1 (es) 2009-01-08
DOP2009000177A (es) 2009-08-15
CA2675442A1 (en) 2008-07-24
WO2008086949A1 (de) 2008-07-24
TN2009000275A1 (en) 2010-10-18
EP2120923A1 (de) 2009-11-25
US8748483B2 (en) 2014-06-10
UY30871A1 (es) 2008-09-02
MA31094B1 (fr) 2010-01-04
RU2009131058A (ru) 2011-02-27
MX2009006913A (es) 2009-08-12
CR10850A (es) 2009-10-16
SI2120923T1 (sl) 2012-10-30
RS52494B (sr) 2013-02-28
PL2120923T3 (pl) 2012-12-31
BRPI0806661A2 (pt) 2011-09-06
CL2008000110A1 (es) 2008-05-16
JP2010515765A (ja) 2010-05-13
ES2390513T3 (es) 2012-11-13
CN101600427A (zh) 2009-12-09
HRP20120763T1 (hr) 2012-10-31
KR20090110834A (ko) 2009-10-22
EP2120923B1 (de) 2012-07-18
DK2120923T3 (da) 2012-10-29

Similar Documents

Publication Publication Date Title
AR064899A1 (es) Uso de derivados de acido de piranona sustituidos para producir medicamentos para tratar el sindrome metabolico
AR032436A1 (es) Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro
AR047516A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparacion y su uso como medicamentos
AR039403A1 (es) Derivados de acil-4-carboxifenilurea y su uso como antidiabetico
ES2330313T3 (es) Derivados de tiofeno como agentes antivirales contra infeccion por flavivirus.
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
AR039690A1 (es) Difenilazetidinonas sustituidas por grupos acidos, medicamentos que comprenden estos compuestos y su uso
AR040352A1 (es) Derivados de indolinfenilsulfonamida
AR112413A1 (es) Formas sólidas de un inhibidor de la cápside del vih
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
AR059505A1 (es) Dihidrodiazepinas utiles como inhibidores de proteina quinasas
ES2589558T3 (es) Derivados de pirimidin pirazolilo
CR10010A (es) Derivados de pirimidina, derivados de benzodiazepinilo y composiciones farmaceuticas que contienen los mismos
AR038686A1 (es) Formulaciones de derivados de androstano y agonistas del adrenoreceptor beta 2 antiinflamatorios
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
NO20100939L (no) Tioksantinderivater som myeloperoksidaseinhibitorer
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
AR074902A1 (es) Derivados de 1,2,4-oxadiazoles agonistas de receptores s1p1
AR035631A1 (es) Compuestos quimicos
AR065932A1 (es) Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas
PE20190909A1 (es) Derivados de 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol ¨3-cinasa delta y gamma
AR034241A1 (es) Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
AR087211A1 (es) ANTAGONISTAS DE CRTh2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal